Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676291 | 0.75 | EPHX2 (0.34) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL134689 | 0.75 | ALDH1A1 (0.50) | EPHX2MEN1MAPK1KMT2AHSD11B1 | |
| SCHEMBL2960096 | 0.74 | HSD11B1 (0.53) | MEN1KMT2AHSD11B1 | |
| SCHEMBL5435228 | 0.74 | MAPK1 (0.41) | EPHX2MEN1MAPK1KMT2AHSD11B1 | |
| SCHEMBL5677065 | 0.73 | HSD11B1 (0.33) | MEN1KMT2AHSD11B1 | |
| SCHEMBL14466039 | 0.73 | EPHX2 (0.33) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL14272254 | 0.73 | EPHX2 (0.33) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL133579 | 0.72 | ALDH1A1 (0.54) | EPHX2MEN1KMT2A | |
| SCHEMBL5439376 | 0.72 | EPHX2 (0.36) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL5677330 | 0.72 | HSD11B1 (0.46) | MEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109542-A4 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7256205-B2 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20070004788-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-7129251-B2 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1497268-A4 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050250758-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-11-10 | — | — | US | disclosed |
| EP-1140066-A4 | NITROSATED AND NITROSYLATED H2 RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6936627-B2 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050187222-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds | NITROMED, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1497268-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-6552047-B2 | For therapy and prophylaxis of gastrointestinal disorders; inflammations, viral infections, multiple sclerosis; decreasing the recurrence of ulcers; facilitating ulcer healing | NITROMED, INC. | 2003-04-22 | — | — | US | disclosed |
| US-20030060492-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | CHIA-EN LIN. | 2003-03-27 | — | — | US | disclosed |
| US-6469065-B1 | COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE | NITROMED, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | disclosed |
| US-20020077343-A1 | H2 RECEPTOR ANTAGONIST COMPOUNDS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSTIONS AND METHODS OF USE | NICOX S.A. (FR) | 2002-06-20 | — | — | US | disclosed |
| EP-1140066-A1 | NITROSATED AND NITROSYLATED H2 RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1109542-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000028988-A1 | NITROSATED AND NITROSYLATED H2 RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187222-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds | ADRB1, ADRB3, ADRA1D | EPHX2 1889/4885MEN1 3376/4885MAPK1 1410/4885 |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | ADRB1, ADRB3, ADRA1D | EPHX2 2015/4885MEN1 3390/4885MAPK1 1614/4885 |
| US-20070004788-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | HRH2, NOS2, NOS1 | EPHX2 933/4885MEN1 1785/4885MAPK1 1911/4885 |
| US-20050250758-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | HRH2, NOS2, NOS1 | EPHX2 933/4885MEN1 1785/4885MAPK1 1911/4885 |
| US-20030060492-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | HRH2, NOS2, HRH1 | EPHX2 669/4885MEN1 1705/4885MAPK1 2225/4885 |
| US-20020077343-A1 | H2 RECEPTOR ANTAGONIST COMPOUNDS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSTIONS AND METHODS OF USE | HRH2, HCAR2, NOS2 | EPHX2 875/4885MEN1 3136/4885MAPK1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.